No connection

Search Results

ISPC vs JAGX

ISPC
iSpecimen Inc.
BEARISH
Price
$0.13
Market Cap
$3.8M
Sector
Healthcare
AI Confidence
95%
JAGX
Jaguar Health, Inc.
BEARISH
Price
$0.37
Market Cap
$4.6M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ISPC
--
JAGX
--
Forward P/E
ISPC
-0.16
JAGX
-0.06
P/B Ratio
ISPC
0.41
JAGX
-0.13
P/S Ratio
ISPC
1.97
JAGX
0.4
EV/EBITDA
ISPC
0.32
JAGX
-1.12

Profitability

Gross Margin
ISPC
1.25%
JAGX
67.21%
Operating Margin
ISPC
-5192.87%
JAGX
-631.9%
Profit Margin
ISPC
0.0%
JAGX
0.0%
ROE
ISPC
-327.77%
JAGX
--
ROA
ISPC
-59.44%
JAGX
-61.46%

Growth

Revenue Growth
ISPC
-96.5%
JAGX
-7.8%
Earnings Growth
ISPC
--
JAGX
--

Financial Health

Debt/Equity
ISPC
0.09
JAGX
--
Current Ratio
ISPC
1.12
JAGX
0.5
Quick Ratio
ISPC
1.11
JAGX
0.07

Dividends

Dividend Yield
ISPC
--
JAGX
--
Payout Ratio
ISPC
0.0%
JAGX
0.0%

AI Verdict

ISPC BEARISH

The company is in severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a total absence of a viable Altman Z-Score. Revenue has collapsed by 96.50% year-over-year, while operating margins have plummeted to -5192.87%, indicating a complete breakdown of the business model. With a 5-year price decline of 99.9% and a technical trend score of 0/100, the stock is in a terminal bearish phase. Despite a low debt-to-equity ratio, the lack of top-line growth and extreme losses make the equity highly speculative and high-risk.

Strengths
Low Debt/Equity ratio (0.09) suggests minimal long-term debt burden
Current Ratio of 1.12 indicates marginal short-term liquidity
Trading at a discount to book value (P/B 0.41)
Risks
Catastrophic revenue decline of -96.50% YoY
Extreme operational inefficiency with -5192.87% operating margin
Severe financial instability indicated by Piotroski F-Score of 1/9
JAGX BEARISH

JAGX exhibits extreme financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.13, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a Quick Ratio of 0.07, suggesting it cannot meet short-term obligations. Despite a positive gross margin, the operating margin is catastrophic at -631.90%, and the stock has collapsed by 92.8% over the last year. The combination of declining revenue and consistent earnings misses points toward a high risk of insolvency.

Strengths
Positive Gross Margin (67.21%)
Low Price-to-Sales ratio (0.40)
Recent reduction in the magnitude of quarterly losses
Risks
Severe liquidity risk (Quick Ratio 0.07)
Negative equity (Price/Book -0.13)
Catastrophic operating losses (-631.90% margin)

Compare Another Pair

ISPC vs JAGX: Head-to-Head Comparison

This page compares iSpecimen Inc. (ISPC) and Jaguar Health, Inc. (JAGX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile